We conclude that MD2 could be a potential therapeutic target for treatment of NAFLD/NASH, and the small molecule MD2 inhibitor, L6H21, was an effective and selective investigative agent for future mechanistic studies and pre‐clinical drug development. This evidence concerns the gene LY96 and metabolic dysfunction-associated steatotic liver disease.